Clinically and orally compatible formulation-manufactured DDX5 (p68)-targeting molecular glue FL118 products exhibit low toxicity but high efficacy against human cancer
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-11-01
|
| Series: | Journal of Pharmaceutical Analysis |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2095177924000984 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846113234330845184 |
|---|---|
| author | Xiang Ling Wenjie Wu Li Yan Leslie Curtin Melanie M. Farrauto Sandra Sexton Anmbreen Jamroze Changjun Yu Christos Fountzilas Dean G. Tang Fengzhi Li |
| author_facet | Xiang Ling Wenjie Wu Li Yan Leslie Curtin Melanie M. Farrauto Sandra Sexton Anmbreen Jamroze Changjun Yu Christos Fountzilas Dean G. Tang Fengzhi Li |
| author_sort | Xiang Ling |
| collection | DOAJ |
| format | Article |
| id | doaj-art-bc7a7e34aa5247839ce2ce1bb6832e77 |
| institution | Kabale University |
| issn | 2095-1779 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Pharmaceutical Analysis |
| spelling | doaj-art-bc7a7e34aa5247839ce2ce1bb6832e772024-12-22T05:27:48ZengElsevierJournal of Pharmaceutical Analysis2095-17792024-11-011411101001Clinically and orally compatible formulation-manufactured DDX5 (p68)-targeting molecular glue FL118 products exhibit low toxicity but high efficacy against human cancerXiang Ling0Wenjie Wu1Li Yan2Leslie Curtin3Melanie M. Farrauto4Sandra Sexton5Anmbreen Jamroze6Changjun Yu7Christos Fountzilas8Dean G. Tang9Fengzhi Li10Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USA; Canget BioTekpharma LLC, Buffalo, New York, 14203, USADepartment of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USA; Canget BioTekpharma LLC, Buffalo, New York, 14203, USADepartment of Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center Buffalo, New York, 14263, USAComparative Oncology Shared Resources, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USAComparative Oncology Shared Resources, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USAComparative Oncology Shared Resources, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USADepartment of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USACalifornia Institute of Technology, Pasadena, CA, 91125, USADepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USA; Developmental Therapeutics (DT) Program, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USA; Pancreatic Cancer Research Center, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USADepartment of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USA; Developmental Therapeutics (DT) Program, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USA; Genitourinary (GU) Oncology Research Center, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USADepartment of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USA; Developmental Therapeutics (DT) Program, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USA; Pancreatic Cancer Research Center, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USA; Genitourinary (GU) Oncology Research Center, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USA; Corresponding author.http://www.sciencedirect.com/science/article/pii/S2095177924000984 |
| spellingShingle | Xiang Ling Wenjie Wu Li Yan Leslie Curtin Melanie M. Farrauto Sandra Sexton Anmbreen Jamroze Changjun Yu Christos Fountzilas Dean G. Tang Fengzhi Li Clinically and orally compatible formulation-manufactured DDX5 (p68)-targeting molecular glue FL118 products exhibit low toxicity but high efficacy against human cancer Journal of Pharmaceutical Analysis |
| title | Clinically and orally compatible formulation-manufactured DDX5 (p68)-targeting molecular glue FL118 products exhibit low toxicity but high efficacy against human cancer |
| title_full | Clinically and orally compatible formulation-manufactured DDX5 (p68)-targeting molecular glue FL118 products exhibit low toxicity but high efficacy against human cancer |
| title_fullStr | Clinically and orally compatible formulation-manufactured DDX5 (p68)-targeting molecular glue FL118 products exhibit low toxicity but high efficacy against human cancer |
| title_full_unstemmed | Clinically and orally compatible formulation-manufactured DDX5 (p68)-targeting molecular glue FL118 products exhibit low toxicity but high efficacy against human cancer |
| title_short | Clinically and orally compatible formulation-manufactured DDX5 (p68)-targeting molecular glue FL118 products exhibit low toxicity but high efficacy against human cancer |
| title_sort | clinically and orally compatible formulation manufactured ddx5 p68 targeting molecular glue fl118 products exhibit low toxicity but high efficacy against human cancer |
| url | http://www.sciencedirect.com/science/article/pii/S2095177924000984 |
| work_keys_str_mv | AT xiangling clinicallyandorallycompatibleformulationmanufacturedddx5p68targetingmoleculargluefl118productsexhibitlowtoxicitybuthighefficacyagainsthumancancer AT wenjiewu clinicallyandorallycompatibleformulationmanufacturedddx5p68targetingmoleculargluefl118productsexhibitlowtoxicitybuthighefficacyagainsthumancancer AT liyan clinicallyandorallycompatibleformulationmanufacturedddx5p68targetingmoleculargluefl118productsexhibitlowtoxicitybuthighefficacyagainsthumancancer AT lesliecurtin clinicallyandorallycompatibleformulationmanufacturedddx5p68targetingmoleculargluefl118productsexhibitlowtoxicitybuthighefficacyagainsthumancancer AT melaniemfarrauto clinicallyandorallycompatibleformulationmanufacturedddx5p68targetingmoleculargluefl118productsexhibitlowtoxicitybuthighefficacyagainsthumancancer AT sandrasexton clinicallyandorallycompatibleformulationmanufacturedddx5p68targetingmoleculargluefl118productsexhibitlowtoxicitybuthighefficacyagainsthumancancer AT anmbreenjamroze clinicallyandorallycompatibleformulationmanufacturedddx5p68targetingmoleculargluefl118productsexhibitlowtoxicitybuthighefficacyagainsthumancancer AT changjunyu clinicallyandorallycompatibleformulationmanufacturedddx5p68targetingmoleculargluefl118productsexhibitlowtoxicitybuthighefficacyagainsthumancancer AT christosfountzilas clinicallyandorallycompatibleformulationmanufacturedddx5p68targetingmoleculargluefl118productsexhibitlowtoxicitybuthighefficacyagainsthumancancer AT deangtang clinicallyandorallycompatibleformulationmanufacturedddx5p68targetingmoleculargluefl118productsexhibitlowtoxicitybuthighefficacyagainsthumancancer AT fengzhili clinicallyandorallycompatibleformulationmanufacturedddx5p68targetingmoleculargluefl118productsexhibitlowtoxicitybuthighefficacyagainsthumancancer |